Panagiotis D.
- Country
- Greece
- Department
- 1st Department of Pathology
Research Overview
- Phase 3 Randomized Open‑Label Study of Elritercept Versus Epoetin Alfa for Anemia in ESA‑Naïve Adults with Lower‑Risk Myelodysplastic Syndromes Requiring RBC Transfusions
- Phase 2/3 Randomized Open‑Label Study of MK‑1045 Versus Blinatumomab in Relapsed/Refractory CD19‑Positive B‑Cell Acute Lymphoblastic Leukemia
- A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE 536) vs Epoetin Alfa for the Treatment of Anemia Due to Revised International Prognostic Scoring System (IPSS-R) Very Low, Low, or Intermediate Risk Myelodysplastic Syndrome (MDS) in Erythropoiesis-stimulating Agent (ESA)-naive Participants who are Non-transfusion Dependent (NTD): The “ELEMENT-MDS” Trial
Data & Insights
Has run more than one trial at 70 of 178 partner sites.
Specializations
Hematologic Malignancies
The investigator specializes in treating various blood disorders with a particular focus on Myelodysplastic Syndrome (MDS) and Chronic Lymphocytic Leukemia (CLL).
- Lower-risk MDS management
- Small Lymphocytic Lymphoma (SLL)
- Blood disorder therapeutics
Their research encompasses innovative treatment approaches for transfusion-dependent patients.
Novel Therapeutic Approaches
The investigator evaluates emerging treatments including luspatercept for MDS and nemtabrutinib for leukemia patients.
- Comparative treatment efficacy
- BTK inhibitor therapies
- Treatment response assessment
Their work includes evaluation of treatment outcomes in previously untreated patients.
Clinical Assessment
The investigator focuses on response criteria evaluation and treatment effectiveness measurement in blood cancers.
- Transfusion dependency assessment
- Overall response rates
- Progression-free survival
Their expertise includes implementing standardized assessment criteria for hematologic conditions.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.